Search

Your search keyword '"Aimilia Tsaroucha"' showing total 2 results
Start Over Author "Aimilia Tsaroucha"
2 results on '"Aimilia Tsaroucha"'

1. Genotyping and phenotyping of alpha1-antitrypsin deficiency Greek patients under augmentation therapy: a multicenter study

Author

Matthaios Speletas, Andriana I. Papaioannou, Timm Greulich, Aikaterini Dimakou, Michael Kitrou, Stavros Tryfon, Effrosyni D. Manali, Zafeirios Sardelis, Lykourgos Kolilekas, Georgia Papadaki, Theodoros Karampitsakos, Eleni Stagaki, Vasiliki Apollonatou, Vasilios Tzilas, Nikolaos Roussakis, Stamatia Markou, Gerasimos Apollonatos, Katerina Vlami, Irini Gerogianni, Demosthenes Bouros, Maria Kallieri, Argyrios Tzouvelekis, Galateia Verykokou, Ioanna Korbila, Gerasimina Tsinti, Zoe Daniil, Ilias Papanikolaou, Athena Prapa, Zoe Tsilogianni, Aimilia Tsaroucha, Elvira-Markela Antonogiannaki, and Spyros Papiris

Subjects
medicine.medical_specialty, business.industry, Disease, Gene mutation, medicine.disease, Liver disease, Genotype-phenotype distinction, Internal medicine, Cohort, medicine, Clinical significance, Allele, business, Genotyping
Abstract

Introduction: Alpha1-antitrypsin (A1AT) deficiency is an autosomal co-dominant disease related to SERPINA-1 gene mutations predisposing to pulmonary emphysema and/or liver disease. Aim: to examine the genotype and phenotype of a Greek cohort of A1AT-deficiency patients. Methods: This multicenter study enrolled A1AT-deficiency patients under augmentation treatment from 8 centers in Greece. Results: 23 adult patients, 61% male, 17.4% non-smokers, diagnosed at a median age (IQR) of 47(42-58) years with A1AT levels of 0.24 (0.04-0.4) g/L were identified. Indications for A1AT measurement were severe obstructive pulmonary disease at the age Conclusion: In contrast with the literature, where Z and S are the most common A1AT-deficiency alleles, the present study reveals extremely rare deleterious variants in Greek A1AT-deficiency patients under augmentation treatment. Further examination of phenotype-genotype associations and outcome is expected to unveil their clinical significance in the future.

Published
2020
Full Text
View/download PDF

2. A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer

Author

Sohia Agelaki, Athina Gerogianni, Athanasios Kotsakis, Aimilia Tsaroucha, Athanasios G. Pallis, Nikolaos Androulakis, Pavlos Papakotoulas, A. Agelidou, Vassilis Georgoulias, M. Agelidou, Lambros Vamvakas, and Nikolaos Kentepozidis

Subjects
Pulmonary and Respiratory Medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Phases of clinical research, Antineoplastic Agents, Vinorelbine, Vinblastine, Gastroenterology, Disease-Free Survival, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Survival rate, Aged, Neoplasm Staging, business.industry, Middle Aged, medicine.disease, Gemcitabine, Surgery, Survival Rate, Regimen, Treatment Outcome, Oncology, Docetaxel, Disease Progression, Drug Therapy, Combination, Female, Cisplatin, business, Progressive disease, medicine.drug, Follow-Up Studies
Abstract

Summary Purpose To evaluate the activity and toxicity of the sequential administration of vinorelbine/cisplatin (VC regimen) followed by the docetaxel/gemcitabine (DG regimen) combination in patients with advanced non-small cell lung cancer (NSCLC). Patients and treatment Fifty-nine previously untreated patients with advanced/metastatic NSCLC received three cycles of cisplatin 80mg/m 2 (day 1), and vinorelbine 30mg/m 2 (days 1 and 8 every 3 weeks; VC regimen), followed by six cycles of docetaxel (65mg/m 2 , day 1) and gemcitabine (1500mg/m 2 , day 1), (DG regimen) every 2 weeks. Results One (1.7%) complete and 26 (44.1%) partial responses were achieved for an overall response rate of 45.8% (95% CI 33.05–58.48%); 12 (20.3%) patients had stable disease and 20 (33.9%) progressive disease. The median time to progression was 5.3 months, the median survival time 12.5 months and the 1-year survival rate 51%. The main toxicity was grade III/IV neutropenia occurring in 25.5% of patients; all other hematologic and non-hematologic toxicities were relatively infrequent. Conclusions The sequential administration of VC and DG regimens was well tolerated and active against advanced NSCLC and merits to be further evaluated against a single doublet.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results